IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES

被引：0
|
作者：
Ganan-Gomez, I. [1 ]
Alfonso, A. [1 ]
Ogoti, Y. [1 ]
Yang, H. [1 ]
Montalban-Bravo, G. [1 ]
Yu, A. C. [2 ]
Silver, S. [2 ]
Clise-Dwyer, K. [1 ]
Garcia-Manero, G. [1 ]
Colla, S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30165-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页码：S34 / S36
页数：3
相关论文
共 50 条
  • [31] Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective casecontrol study
    Jabbour, Elias
    Mathisen, Michael S.
    Garcia-Manero, Guillermo
    Champlin, Richard
    Popat, Uday
    Khouri, Issa
    Giralt, Sergio
    Kadia, Tapan
    Chen, Julianne
    Pierce, Sherry
    Koca, Ebru
    Daver, Naval
    Tanaka, Maria
    Rondon, Gabriela
    Oran, Betul
    Parmar, Simrit
    Kantarjian, Hagop
    de Lima, Marcos
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (03) : 198 - 200
  • [32] A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
    Radakovich, Nathan
    Sallman, David A.
    Buckstein, Rena
    Brunner, Andrew
    Dezern, Amy
    Mukerjee, Sudipto
    Komrokji, Rami
    Al-Ali, Najla
    Shreve, Jacob
    Rouphail, Yazan
    Parmentier, Anne
    Mamedov, Alexandre
    Siddiqui, Mohammed
    Guan, Yihong
    Kuzmanovic, Teodora
    Hasipek, Metis
    Jha, Babal
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    Nazha, Aziz
    ISCIENCE, 2022, 25 (10)
  • [33] Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
    Klimek, Virginia M.
    Dolezal, Emily K.
    Tees, Michael T.
    Devlin, Sean M.
    Stein, Karen
    Romero, Alejandro
    Nimer, Stephen D.
    LEUKEMIA RESEARCH, 2012, 36 (09) : 1093 - 1097
  • [34] Outcome After Hypomethylating Agents Failure in Patients With IDH1 Mutated Myelodysplastic Syndromes
    Abuhelwa, Ziad
    Al Ali, Najla
    Xie, Zhuoer
    Chan, Onyee
    Seongseok, Yun
    Kuykendall, Andrew
    Walker, Alison
    Lancet, Jeffrey
    Padron, Eric
    Sallman, David
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S391 - S391
  • [35] Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents
    Roberts, Daniel A.
    Steensma, David P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2015, 10 (03) : 318 - 328
  • [36] Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents
    Daniel A. Roberts
    David P. Steensma
    Current Hematologic Malignancy Reports, 2015, 10 : 318 - 328
  • [37] PATTERNS OF CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS
    Faria, C.
    Chang, E.
    Powers, A.
    Cherepanov, D.
    Broder, M.
    VALUE IN HEALTH, 2012, 15 (04) : A228 - A228
  • [38] The Effects of Hypomethylating Agents on Mutational Profiles in Patients with Myelodysplastic Syndromes
    Qiu, Jihui
    Velu, Priya
    Rosenbaum, Jason
    Babushok, Daria
    Bagg, Adam
    MODERN PATHOLOGY, 2019, 32
  • [39] New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
    Loiseau, Clemenee
    Ali, Ashfaq
    Itzykson, Raphael
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (08) : 661 - 672
  • [40] The Effects of Hypomethylating Agents on Mutational Profiles in Patients with Myelodysplastic Syndromes
    Qiu, Jihui
    Velu, Priya
    Rosenbaum, Jason
    Babushok, Daria
    Bagg, Adam
    LABORATORY INVESTIGATION, 2019, 99
12345